Reata Pharmaceuticals is currently recruiting participants for its Phase 3 CATALYST trial assessing the effectiveness of bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). After analysis of the Phase 2 LARIAT study (NCT02036970) results in pulmonary hypertension (PH) and interim data of the first 100…

Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile in patients with PH associated with interstitial lung disease (ILD), according to top-line results from a Phase 2 clinical trial. ILD is a group of several lung…

Reata Pharmaceuticals announced that pulmonary arterial hypertension (PAH) patients treated with bardoxolone methyl showed significant improvements in kidney function that were sustained for two years without adverse outcomes. The results from the long-term follow-up of the Phase 2 LARIAT study (NCT02036970) showing a two-year improvement in kidney…

Three ongoing clinical trials are recruiting additional participants to allow for more robust assessments of Reata Pharmaceuticals’ bardoxolone methyl therapy as a potential treatment for various forms of pulmonary hypertension. Two of the trials — the Phase 3 CATALYST (NCT02657356) trial, which examines…

Reata Pharmaceuticals is enrolling participants for two ongoing clinical trials of bardoxolone methyl as a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) caused by an underlying interstitial lung disease. Bardoxolone methyl belongs to a class of small molecules that target an important transcription factor called Nrf2.

Reata Pharmaceuticals has enrolled the first patient in its Phase 3 CATALYST trial (NCT02657356), exploring the potential benefits of bardoxolone methyl in people with pulmonary arterial hypertension (PAH) linked to connective tissue disease. The trial is continuing to recruit participants. The company also reported that data from the ongoing Phase 2 LARIAT…

Reata Pharmaceuticals recently provided an update on its clinical candidates and their developmental, including its Phase 2 proof-of-concept studies into bardoxolone methyl as a potential treatment for various types of pulmonary hypertension and omaveloxolone for neuromuscular diseases. Bardoxolone methyl is being developed for patients with pulmonary arterial hypertension (PAH), or high…

Reata Pharmaceuticals has reported positive interim results from the extension Phase 2 LARIAT clinical trial assessing bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). The LARIAT trial is assessing the efficacy, safety, and tolerability of bardoxolone methyl compared to a placebo in patients with PAH. The study aims to determine the recommended…

Reata Pharmaceuticals, Inc., recently announced in a press release the pricing of its initial public offering of 5,500,000 shares of its Class A common stock at $11.00 per share, before underwriting discounts and commissions. The Irving, Texas-based clinical-stage biopharmaceutical company says it intends to use net proceeds from the offering…

Irving, Texas-based Reata Pharmaceuticals, Inc. has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for its pulmonary arterial hypertension (PAH) treatment. The FDA’s Office of Orphan Products Development (OOPD) awarded the designation to bardoxolone methyl due to its novel…

Reata Pharmaceuticals, Inc. is a privately held company located in Irving, Texas aiming to translate innovative research into breakthrough medicines for difficult-to-treat diseases that have significant unmet needs. Their approach specifically involves developing a novel class of drugs with potent transcriptional activity, called antioxidant inflammation modulators (AIMs), which can…

Irving, Texas based Reata Pharmaceuticals, Inc. has enrolled the first patient in a Phase 2 dose ranging study examining the safety, tolerability, and efficacy of bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). PAH is a life-threatening disease involving endothelial dysfunction, vasoconstriction in small pulmonary arteries, aberrant…